leadf
logo-loader
viewAmplia Therapeutics Ltd
(
ASX:ATX
)

Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone

Amplia Therapeutics Limited's (ASX:ATX) Dr John Lambert speaks to Proactive's Andrew Scott following the news they've begun dosing the first volunteers in its Phase 1 clinical trial of AMP945. The molecule's being developed for difficult-to-treat cancers and fibrotic diseases. Amplia expects to complete dosing in the trial during the first half of next year, which should allow reporting of top-line results around the middle of 2021.

Quick facts: Amplia Therapeutics Ltd

Follow
ASX:ATX

Price: 0.21 AUD

Market Cap: $26.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Amplia Therapeutics details upcoming Phase 2 pancreatic cancer trial

Amplia Therapeutics Ltd (ASX:ATX)'s CEO John Lambert tells Proactive they've completed the design for a Phase 2 clinical trial of its Focal Adhesion Kinase (FAK) inhibitor, AMP945 in newly diagnosed patients receiving first-line therapy for pancreatic cancer. The company plans to initiate...

5 days, 12 hours ago

2 min read